This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor.—The Policy Perspective by Dr Kodish and colleagues¹ summarizes important clinical considerations regarding genetic testing for breast cancer susceptibility. The authors endorse the statement of the American Society of Clinical Oncology (ASCO)² that further research in this area is essential, but argue that restricting genetic testing to the research setting may not be in the patient's best interest. In this regard, it is perhaps worth noting that testing for cancer genetic susceptibility is now being marketed by more than a dozen commercial laboratories.

Several points not mentioned in the article by Kodish et al deserve emphasis here. First, the need for greater education of health care professionals was highlighted in the original ASCO statement and has been a major focus for the organization. In collaboration with other professional groups, ASCO organized and conducted a "Train the Trainer" workshop in 1997. A special Task Force on Cancer Genetics . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Genetic Testing for Cancer Risk: How to Reconcile the Conflicts
Eric Kodish, Georgia L. Wiesner, Maxwell Mehlman, and Thomas Murray
JAMA. 1998;279(3):179-181.
EXTRACT | FULL TEXT